Designed, developed, and delivered by CEC Oncology Neurofibromatosis type 1 (NF1) is a complex condition of immense clinical gravity, and though the traditional management paradigm has long been circumscribed by a limited and ineffectual trimodal combination of surgery, radiation, and surveillance, the recent emergence of trial data in support of targeted medical therapies is renewing […]
Read more
Brought to you by BD Launched in 2017, the PowerFlowTM Implantable Apheresis IV Port is a high-flow, power-injectable1 port designed and indicated specifically for therapeutic apheresis. Because of its newness to the market, BD has taken steps to ensure that educational tools are ready and available to patients, nurses, and other healthcare professionals. We believe […]
Read more
Brought to you by The Aplastic Anemia and MDS International Foundation The Aplastic Anemia and MDS International Foundation invites you to participate in our ONS Congress satellite symposium, The Spectrum of MDS: Disease Management and Patient Education in the ONS Congress virtual platform. MDS is challenging to diagnose, but the evolving genomic and immunologic landscape […]
Read more
Jen Krause, Director of National Conferences and Meetings More than 3,200 oncology nurses came together virtually for the 46th Annual ONS Congress™ to learn, connect, and share. From fast-paced live Q&As with invited speakers to heated competition in the Virtual Challenge, attendees made (and are still making) the most of their time in the digital space. This year’s […]
Read more
Brought to you by Fresenius Kabi Healthcare providers and patients can expect the same efficacy and safety from a biosimilar as from the originator biologic, as biosimilars and originators are highly similar in terms of structure, function, and quality. Biosimilars also have the potential to reshape the biologic landscape and can improve patient costs and […]
Read more
Brought to you by Puma Biotechnology, Inc. Looking for additional support tools for your patients taking NERLYNX® (neratinib)? The NERLYNX mentor program connects patients with someone who currently takes or has taken NERLYNX to provide support and share their experiences. Hearing from someone who has taken NERLYNX helps patients: • Learn about another person’s real-life […]
Read more
In ER+/HER2- metastatic breast cancer (mBC) COULD ADVANCEMENTS IN ENDOCRINE THERAPY UNLOCK A BRIGHTER PATH FORWARD? Content created and sponsored by Sanofi Genzyme Endocrine therapies (Els) have advanced the care of patients with ER+/HER2- mBC, yet due to complex tumor mechanisms and endocrine resistance, progression still persists.1-3 Currently, -50% of ER+/HER2- mBC patients that are […]
Read more
Brought to you by Janssen Oncology Subcutaneous Treatment for Multiple Myeloma Janssen Oncology April 27, 2021 Looking to learn more about a subcutaneous treatment for multiple myeloma? You can click here to learn more, including: • Clinical data for subcutaneous treatment • Overview of administration of this treatment • Dosing schedule, preparation, storage and handling, […]
Read more
Brought to you by Research To Practice Join Dr Neil Love and 29 invited clinical investigators for the continuation of this unique 11-part NCPD-accredited series designed specifically for oncology nurses. prior to these sessions, Dr Love will be sitting down with nurses in clinical practice from across the country as they present challenging cases from their practices. These […]
Read more
Brought to you by Physicians’ Education Resource®, LLC Although multiple myeloma (MM) remains incurable, the past 15 years have yielded improved clinical outcomes with response rates rising as high as 30% with monotherapy and up to 90% with combination therapies. With new treatments that offer the potential to improve progression-free survival and overall survival for […]
Read more
May 11, 2021
